電子ドラッグデリバリーシステム (DDS) の世界市場 - 2024年までの予測：電子ウェアラブル輸液ポンプ・電子自動注入器・電子注入ペン・電子吸入具
Electronic Drug Delivery Systems Market by Type (Electronic Wearable Infusion Pump, Autoinjectors, Injection Pens, Electronic Inhalers), Indication (Diabetes, Multiple Sclerosis, Cardiovascular Disease, Asthma & COPD) - Global Forecast to 2024
|出版日||ページ情報||英文 125 Pages
|電子ドラッグデリバリーシステム (DDS) の世界市場 - 2024年までの予測：電子ウェアラブル輸液ポンプ・電子自動注入器・電子注入ペン・電子吸入具 Electronic Drug Delivery Systems Market by Type (Electronic Wearable Infusion Pump, Autoinjectors, Injection Pens, Electronic Inhalers), Indication (Diabetes, Multiple Sclerosis, Cardiovascular Disease, Asthma & COPD) - Global Forecast to 2024|
|出版日: 2019年10月15日||ページ情報: 英文 125 Pages||
世界の電子ドラッグデリバリーシステム (DDS) 市場は、2019年の78億米ドルから2024年までに119億米ドルへ達すると予測され、予測期間中は8.7%のCAGR (年間複合成長率) が見込まれています。同市場は主に北米 & 欧州における好ましい医療費償還シナリオ、糖尿病 & 心血管疾患といった標的疾患の有病率の増加、および技術・電子ドラッグデリバリーシステム (DDS) の設計における進歩などによって促進されています。また、中国やインドなどの新興市場は、今後数年のうちに市場参入企業へ潜在的な成長機会をもたらすと見込まれています。
当レポートでは、世界の電子ドラッグデリバリーシステム (DDS) 市場について調査分析し、市場概要、産業動向、各セグメント別・地域別による市場の分析と予測、競合情勢、主要企業などについて、体系的な情報を提供しています。
"The electronic drug delivery systems market is projected to grow at a CAGR of 8.7% during the forecast period (2019-2024)."
The electronic drug delivery systems market is projected to reach USD 11.9 billion by 2024 from USD 7.8 billion in 2019, at a CAGR of 8.7%. The growth of the electronic drug delivery systems market is mainly driven by the favorable reimbursement scenario in North America & Europe, the growing prevalence of target diseases such as diabetes & cardiovascular disease, and advancements in technologies and designs of electronic drug delivery systems. Additionally, emerging markets such as China and India are expected to offer potential growth opportunities to market players in the coming years.
Based on type, the electronic drug delivery systems market is segmented into electronic wearable infusion pumps, electronic autoinjectors, electronic injection pens, and electronic inhalers. The electronic wearable infusion pumps segment is expected to account for the largest market share of the electronic drug delivery systems market in 2019. This is mainly due to the high prevalence of diabetes and the increasing availability of commercial infusion pumps for diabetes treatment.
The diabetes segment accounted for the largest share of the market in 2018. This is mainly due to the high availability of electronic drug delivery devices such as insulin pumps and injection pens by major market players in comparison to other therapeutic areas, rising adoption of mobile apps for diabetes management, and increasing penetration of digital platforms (such as smartphones, tablet PCs, and personal digital assistants). For instance, in June 2018, Insulet Corporation (US), received the FDA approval for its Omnipod DASH Insulin Management System for diabetes management. Similarly, in June 2018, Tandem Diabetes Care (US), received the CE mark for its t:slim X2 Insulin Pump for diabetes management.
North America is expected to account for the largest share of the global electronic drug delivery system market in 2019, followed by Europe. Additionally, the US is also expected to witness the highest CAGR during the forecast period. This can primarily be attributed to the high incidence and prevalence of chronic conditions such as diabetes, asthma, CVD, and multiple sclerosis in the US. For instance, according to the IDF, there were about 30.2 million people suffering from diabetes in the US in 2017, and this figure is estimated to reach 35.6 million by 2045. Similarly, in 2017, approximately 25.2 million people had asthma in the US (Source:CDC). Furthermore, According to the American Heart Association, in 2017, about 801,000 deaths in the US are due to CVD. Obesity is a major risk factor for CVD and diabetes in the US; around 36.5% of adults in the country are obese (Source: CDC).
A breakdown of the primary participants referred to for this report is provided below:
The prominent players in the electronic drug delivery systems market are: United Therapeutics Corporation (US), Insulet Corporation (US), Novo Nordisk (Denmark), Bayer AG (Germany), Medtronic plc (Ireland), AstraZeneca (UK), Tandem Diabetes Care (US), Merck Group (Germany), and Amgen (US).
The report analyzes the electronic drug delivery system market and aims at estimating the market size and future growth potential of the electronic drug delivery systems market and the different segments such as diabetes, multiple sclerosis, cardiovascular disease, asthma & COPD, and other indications (growth hormone therapy, primary immunodeficiency disease, thalassemia, and Parkinson's disease). The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product & service offerings, and recent developments.
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a greater share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies for strengthening their market presence.
This report provides insights on the following pointers:
(Business overview, Products offered, Recent Developments)*
Details on Business overview, Products offered, Recent Developments might not be captured in case of unlisted companies.